Physician profile
Michael Edward Ruff
NPI 1679532576
$5,351.21
in general payments reported to CMS, 2019-2025
33 companies · $391 in 2025
The $391 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $953 · 2021: $1,247 · 2022: $649 · 2023: $1,012 · 2024: $518 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,920.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $750.25 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Regeneron Healthcare Solutions, INC. | $732.76 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $574.86 | 2019-2025 | Nucala, Trelegy Ellipta |
| Covis Pharma Gmbh | $538.37 | 2019-2022 | |
| Alk-Abello, INC | $301.71 | 2019-2024 | Odactra, Ragwitek, Grastek |
| Grifols USA, LLC | $237.29 | 2019-2023 | Xembify, Gamunex-C |
| Octapharma USA, INC. | $235.29 | 2019-2022 | |
| Pharming Healthcare, INC. | $213.84 | 2019-2023 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $199.32 | 2019-2023 | |
| Kaleo, INC. | $195.15 | 2020-2023 | Auvi-Q |
| Genzyme Corporation | $158.55 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $151.50 | 2022-2024 | Takhzyro, Cuvitru, Hyqvia |
| Novartis Pharmaceuticals Corporation | $128.39 | 2019-2024 | |
| Optinose US, INC. | $118.67 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.58 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $99.23 | 2020-2024 | |
| Abbvie INC. | $85.38 | 2022-2023 | Rinvoq |
| Hospira, INC. | $71.02 | 2024-2025 | |
| Csl Behring | $54.87 | 2020-2023 | Hizentra |
| Leo Pharma INC. | $51.87 | 2022-2023 | Adbry |
| Biocryst Pharmaceuticals, INC. | $46.18 | 2020 | |
| Organon LLC | $41.97 | 2025 | Vtama |
| Blueprint Medicines Corporation | $38.03 | 2023 | Ayvakit |
| Amgen INC. | $38.01 | 2021-2023 | Tezspire |
| Shire North American Group INC | $36.98 | 2019 | |
| Biocryst US Sales Co., LLC | $32.77 | 2021 | |
| Azurity Pharmaceuticals, INC. | $21.94 | 2025 | Alvesco |
| Insmed, INC. | $19.07 | 2025 | Arikayce |
| Incyte Corporation | $16.86 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $16.29 | 2025 | Neffy |
| Uswm, LLC | $14.73 | 2021 | |
| Hikma Pharmaceuticals USA | $14.63 | 2022 | |
| Almirall LLC | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ruff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.